Advertisement

Renal Function and Effect of Statin Therapy on Cardiovascular Outcomes in Patients Undergoing Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2)

      Although statin therapy is essential for secondary cardiovascular prevention, the therapeutic effect of statins on cardiovascular outcomes in patients with advanced chronic kidney disease (CKD) after coronary revascularization has not been fully elucidated. In the CREDO-Kyoto Registry Cohort-2, 14,706 patients who underwent first coronary revascularization were divided into 4 strata based on estimated glomerular filtration rate (eGFR) or status of hemodialysis (HD). Patients in each stratum were further divided into 2 groups based on statin therapy at discharge: non-CKD stratum (eGFR ≥60 ml/min/1.73 m2), 8,959 patients (statin, n = 4,747; no statin, n = 4,212); mild CKD stratum (eGFR ≥30 to <60 ml/min/1.73 m2), 4,567 patients (statin, n = 2,135; no statin, n = 2,432); severe CKD stratum (eGFR <30 ml/min/1.73 m2), 608 patients (statin, n = 229; no statin, n = 379); and HD stratum, 572 patients (statin, n = 117; no statin, n = 455). Median follow-up duration was 956 days (interquartile range 699 to 1,245). Adjusted risk for major adverse cardiovascular events (MACEs; composite of cardiovascular death, myocardial infarction, or stoke) was significantly lower in the statin group than in the no-statin group in the non-CKD (hazard ratio 0.8, 95% confidence interval 0.68 to 0.95, p = 0.01) and mild CKD (hazard ratio 0.69, 95% confidence interval 0.56 to 0.84, p = 0.0002) strata. However, a significant association of statin therapy and lower risk for MACEs was not seen in the severe CKD (hazard ratio 0.91, 95% confidence interval 0.6 to 1.38, p = 0.65) and HD (hazard ratio 1.04, 95% confidence interval 0.64 to 1.69, p = 0.87) strata. In conclusion, statin therapy was associated with significantly lower risk for MACEs in patients with non-CKD and mild CKD undergoing coronary revascularization. However, therapeutic benefits of statins were not apparent in patients with severe CKD and HD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Anavekar N.S.
        • McMurray J.J.
        • Velazquez E.J.
        • Solomon S.D.
        • Kober L.
        • Rouleau J.L.
        • White H.D.
        • Nordlander R.
        • Maggioni A.
        • Dickstein K.
        • Zelenkofske S.
        • Leimberger J.D.
        • Califf R.M.
        • Pfeffer M.A.
        Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
        N Engl J Med. 2004; 351: 1285-1295
        • McCullough P.A.
        Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
        Circulation. 2006; 114: 6-7
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • MacFarlane P.W.
        • McKillop J.H.
        • Packard C.J.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr., A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        • JUPITER Study Group
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
      1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Ridker P.M.
        • MacFadyen J.
        • Cressman M.
        • Glynn R.J.
        Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention—An Intervention Trial Evaluating Rosuvastatin) trial.
        J Am Coll Cardiol. 2010; 55: 1266-1273
        • Tonelli M.
        • Moyé L.
        • Sacks F.M.
        • Kiberd B.
        • Curhan G.
        • Cholesterol and Recurrent Events (CARE) Trial Investigators
        Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.
        Ann Intern Med. 2003; 138: 98-104
        • Koren M.J.
        • Davidson M.H.
        • Wilson D.J.
        • Fayyad R.S.
        • Zuckerman A.
        • Reed D.P.
        • ALLIANCE Investigators
        Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
        Am J Kidney Dis. 2009; 53: 741-750
        • Wanner C.
        • Krane V.
        • März W.
        • Olschewski M.
        • Mann J.F.
        • Ruf G.
        • Ritz E.
        • German Diabetes and Dialysis Study Investigators
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Fellstrom B.C.
        • Jardine A.G.
        • Schmieder R.E.
        • Holdaas H.
        • Bannister K.
        • Beutler J.
        • Chae D.W.
        • Chevaile A.
        • Cobbe S.M.
        • Gronhagen-Riska C.
        • De Lima J.J.
        • Lins R.
        • Mayer G.
        • McMahon A.W.
        • Parving H.H.
        • Remuzzi G.
        • Samuelsson O.
        • Sonkodi S.
        • Sci D.
        • Suleymanlar G.
        • Tsakiris D.
        • Tesar V.
        • Todorov V.
        • Wiecek A.
        • Wuthrich R.P.
        • Gottlow M.
        • Johnsson E.
        • Zannad F.
        Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
        N Engl J Med. 2009; 360: 1395-1407
        • Baigent C.
        • Landray M.J.
        • Reith C.
        • Emberson J.
        • Wheeler D.C.
        • Tomson C.
        • Wanner C.
        • Krane V.
        • Cass A.
        • Craig J.
        • Neal B.
        • Jiang L.
        • Hooi L.S.
        • Levin A.
        • Agodoa L.
        • Gaziano M.
        • Kasiske B.
        • Walker R.
        • Massy Z.A.
        • Feldt-Rasmussen B.
        • Krairittichai U.
        • Ophascharoensuk V.
        • Fellström B.
        • Holdaas H.
        • Tesar V.
        • Wiecek A.
        • Grobbee D.
        • de Zeeuw D.
        • Grönhagen-Riska C.
        • Dasgupta T.
        • Lewis D.
        • Herrington W.
        • Mafham M.
        • Majoni W.
        • Wallendszus K.
        • Grimm R.
        • Pedersen T.
        • Tobert J.
        • Armitage J.
        • Baxter A.
        • Bray C.
        • Chen Y.
        • Chen Z.
        • Hill M.
        • Knott C.
        • Parish S.
        • Simpson D.
        • Sleight P.
        • Young A.
        • Collins R.
        • SHARP Investigators
        The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
        Lancet. 2011; 377: 2181-2192
        • Kimura T.
        • Morimoto T.
        • Furukawa Y.
        • Nakagawa Y.
        • Kadota K.
        • Iwabuchi M.
        • Shizuta S.
        • Shiomi H.
        • Tada T.
        • Tazaki J.
        • Kato Y.
        • Hayano M.
        • Abe M.
        • Tamura T.
        • Shirotani M.
        • Miki S.
        • Matsuda M.
        • Takahashi M.
        • Ishii K.
        • Tanaka M.
        • Aoyama T.
        • Doi O.
        • Hattori R.
        • Tatami R.
        • Suwa S.
        • Takizawa A.
        • Takatsu Y.
        • Takahashi M.
        • Kato H.
        • Takeda T.
        • Lee J.D.
        • Nohara R.
        • Ogawa H.
        • Tei C.
        • Horie M.
        • Kambara H.
        • Fujiwara H.
        • Mitsudo K.
        • Nobuyoshi M.
        • Kita T.
        Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan.
        Cardiovasc Interv Ther. 2011; 26: 234-245
        • Natsuaki M.
        • Furukawa Y.
        • Morimoto T.
        • Nakagawa Y.
        • Ono K.
        • Kaburagi S.
        • Inada T.
        • Mitsuoka H.
        • Taniguchi R.
        • Nakano A.
        • Kita T.
        • Sakata R.
        • Kimura T.
        • CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators
        Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in japanese patients after coronary revascularization.
        Circ J. 2012; 76: 1369-1379
        • Natsuaki M.
        • Nakagawa Y.
        • Morimoto T.
        • Ono K.
        • Shizuta S.
        • Furukawa Y.
        • Kadota K.
        • Iwabuchi M.
        • Kato Y.
        • Suwa S.
        • Inada T.
        • Doi O.
        • Takizawa A.
        • Nobuyoshi M.
        • Kita T.
        • Kimura T.
        • CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators
        Impact of statin therapy on late target lesion revascularization after sirolimus-eluting stent implantation (from the CREDO-Kyoto Registry Cohort-2).
        Am J Cardiol. 2012; 109: 1387-1396
        • Tokushige A.
        • Shiomi H.
        • Morimoto T.
        • Furukawa Y.
        • Nakagawa Y.
        • Kadota K.
        • Iwabuchi M.
        • Shizuta S.
        • Tada T.
        • Tazaki J.
        • Kato Y.
        • Hayano M.
        • Abe M.
        • Ehara N.
        • Inada T.
        • Kaburagi S.
        • Hamasaki S.
        • Tei C.
        • Nakashima H.
        • Ogawa H.
        • Tatami R.
        • Suwa S.
        • Takizawa A.
        • Nohara R.
        • Fujiwara H.
        • Mitsudo K.
        • Nobuyoshi M.
        • Kita T.
        • Kimura T.
        • CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators
        Incidence and outcome of surgical procedures after coronary bare-metal and drug-eluting stent implantation: a report from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
        Circ Cardiovasc Interv. 2012; 5: 237-246
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Matsuo S.
        • Imai E.
        • Horio M.
        • Yasuda Y.
        • Tomita K.
        • Nitta K.
        • Yamagata K.
        • Tomino Y.
        • Yokoyama H.
        • Hishida A.
        Revised equations for estimated GFR from serum creatinine in Japan.
        Am J Kidney Dis. 2009; 53: 982-992
        • Petronio A.S.
        • Amoroso G.
        • Limbruno U.
        • Papini B.
        • De Carlo M.
        • Micheli A.
        • Ciabatti N.
        • Mariani M.
        Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound.
        Am Heart J. 2005; 149: 520-526
        • Bakris G.L.
        Lipid disorders in uremia and dialysis.
        Contrib Nephrol. 2012; 178: 100-105
        • März W.
        • Genser B.
        • Drechsler C.
        • Krane V.
        • Grammer T.B.
        • Ritz E.
        • Stojakovic T.
        • Scharnagl H.
        • Winkler K.
        • Holme I.
        • Holdaas H.
        • Wanner C.
        • German Diabetes and Dialysis Study Investigators
        Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
        Clin J Am Soc Nephrol. 2011; 6: 1316-1325
        • Strippoli G.F.
        • Navaneethan S.D.
        • Johnson D.W.
        • Perkovic V.
        • Pellegrini F.
        • Nicolucci A.
        • Craig J.C.
        Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.
        BMJ. 2008; 336: 645-651
        • Sandhu S.
        • Wiebe N.
        • Fried L.F.
        • Tonelli M.
        Statins for improving renal outcomes: a meta-analysis.
        J Am Soc Nephrol. 2006; 17: 2006-2016
        • Perkovic V.
        • Verdon C.
        • Ninomiya T.
        • Barzi F.
        • Cass A.
        • Patel A.
        • Jardine M.
        • Gallagher M.
        • Turnbull F.
        • Chalmers J.
        • Craig J.
        • Huxley R.
        The relationship between proteinuria and coronary risk: a systematic review and meta-analysis.
        PLoS Med. 2008; 5: e207